The present invention relates to polyphosphazenes, polyurethanes based on these polyphosphazenes, methods for their manufacture and hydrogels based on the polyurethanes. The invention further relates to the use of the hydrogels in medical, veterinary and agricultural applications.

Poly(organo)phosphazenes are a family of inorganic molecular hybrid polymers with very diverse properties. The article “Preparation of polyphosphazenes: a tutorial review” by S. Rothemund and I. Teasdale, Chem. Soc. Rev., 2016, 45, 5200 gives an overview over the field. WO 2001/07505 A1 relates to compositions of polyphosphazene-containing polymers and methods of preparation thereof. The disclosed compositions encompass telechelic functionalized polyphosphazenes and a variety of block and graft polyphosphazene - poly styrene, polyphosphazene-polysiloxane, and polyphosphazene-ROMP of norbornene copolymers. Methods for the preparation of such compositions generally involve generation of a polydichlorophosphazene species, attachment of a function group to the resultant polyphosphazene compound, and coupling the functionalized polyphosphazene with a corresponding organic or inorganic polymers or polymerizing the functionalized polyphosphazene with corresponding organic molecules.

WO 2013/190260 A2 discloses substituted poly(phosphazene) compounds comprising a combination of units having one or more of the structures (i) to (iii) wherein: the combination comprises R ₁ and R ; each R ₁ , is independently an optionally substituted alkyl- or alkyl ether-based side chain containing an isocyanate -reactive moiety, an epoxide- reactive moiety, an amine-reactive moiety, a supramolecular noncovalent bonding moiety, or combinations thereof; and each R is independently an optionally substituted alkyl- or alkyl ether- based side chain containing nitro, nitramine, nitrate ester, azide, an ammonium compound moiety with energetic counter-ion, or combinations thereof. Methods of making the compounds are also described.

WO 2015/192158 A1 relates to a polymer for tissue engineering from biodegradable polyphosphazenes, having photopolymerizable side groups, wherein the side groups of the polyphosphazenes are formed exclusively from amino acids and/or amino acid derivatives, which are bonded to the backbone of the polyphosphazene via the amino group of the amino acid and to a spacer attached to the acid group with a carbon chain of length m, which has a vinyl group at the free end, wherein m = 0 to m = 10.

Hydrogels are crosslinked 3-D polymeric networks with high water and biological liquids uptake capacity. They can structurally resemble soft tissue or a cell of the body and hydrogels have a wide application area such as drug delivery systems, tissue engineering, and wound dressings. Among these biomedical applications, polyurethane-based hydrogels have been widely used in drug release applications owing to their good mechanical strength and easy applicability to drugs and they are suitable for drug encapsulation, transportation and release.

Despite their formal similarity to peptide bonds, the urethane groups in polyurethanes have been found challenging to biologically degrade. A polyurethane hydrogel with increased susceptibility to hydrolysis would therefore be desirable.

Accordingly, a polyphosphazene as described in claim 1 is provided. This polyphosphazene bears NCO-reactive hydrogen atoms and can be cross-linked with polyisocyanates; this is the subject of claim 8 and method claim 9. The method according to claim 7 concerns the synthesis of polyphosphazenes with NCO-reactive hydrogen atoms. Hydrogels obtained from such polyurethanes are the subject of claim 12. Their uses are covered in claims 14 and 15. Advantageous embodiments are the subject of the dependent claims. They may be combined freely unless the context clearly indicates otherwise.

A polyphosphazene according to the invention has the general formula (I): where each radical R is, independent of other radicals R, an organic radical which does not contain a terminal group with an NCO-reactive hydrogen atom; each radical R ₁ is, independent of other radicals R ₁ , an organic rest; each radical X is, independent of other radicals X, an organic rest and n is zero or a positive integer and furthermore has the property that each radical ZH is, independent of other radicals ZH, a group comprising an NCO-reactive hydrogen atom.

Without wishing to be bound by theory it is believed that the polyphosphazenes according to the invention advantageously combines the reactivity with NCO groups to form polyurethanes and the possibility of hydrolytic cleavage to give a degradable or even bio-degradable polymer. Furthermore, such polyurethanes may be useful in the formation of hydrogels.

The degree of polymerization may be such that the number n in formula (I) is ≥ 3 to ≤ 1000 and preferably ≥ 10 to ≤ 100.

As used herein, the term “NCO-reactive hydrogen atom” denotes a hydrogen atom in the molecule which is able to react with an isocyanate functional group. The most common NCO- reactive hydrogen atoms are those bond to nitrogen, oxygen or sulfur atoms.

In the polyphosphazene according to the invention it is provided that the radicals R which are bond to the backbone of the polymer chain do not contain terminal groups with NCO-reactive hydrogen atoms. This is in contrast to the polymers of WO 2013/190260 A2 and leads to predominantly linear or fully linear polyurethanes.

A terminal group in the radical R is understood to be a functional group attached to the carbon atom within R having the most carbon-carbon bonds between itself and the phosphorus atom to which R is connected. In the event that the functional group is bound to a cyclic structure, positional isomers are disregarded. Hence, in an OH group bound to a phenyl group it would not make a difference whether the OH group is in ortho, meta or para-position to the remainder of R bound to the phenyl group.

The individual radicals R may be branched or unbranched and may comprise substituted or unsubstituted alkylene groups and/or substituted or unsubstituted arylene groups.

The individual radicals R may comprise a heteroatom such as N, O or S with which R is bonded to the respective phosphorus atom. This can be achieved by synthetic pathways where an amide, alkoxide or thiolate nucleophile substitutes a leaving group such as a chloride anion previously bond to the phosphorus atom.

Preferably the individual radicals R of the polyphosphazene (I) do not contain any NCO- reactive hydrogen atoms, in particular do not contain an OH group, an SH group or a primary amino group. It is noted that in a secondary amino group which can be formed by the reaction of a primary amino group with a chlorophosphazene group in the presence of a base (for example, with glycine methyl ester or 3-aminopropyl morpholine as the amine starting material) there is not considered to be an NCO-reactive hydrogen atom.

The individual radicals R ₁ may be branched or unbranched and may comprise substituted or unsubstituted alkylene groups and/or substituted or unsubstituted arylene groups.

The individual radicals R ₁ may comprise a heteroatom such as N, O or S with which R ₁ is bonded to the respective phosphorus atom. This can be achieved by synthetic pathways where an amide, alkoxide or thiolate nucleophile substitutes a leaving group such as a chloride anion previously bond to the phosphorus atom.

The individual radicals R ₁ may be the same as the individual radicals R or they may be different. It is preferred that the individual radicals R ₁ are different from the individual radicals R.

The individual radicals R and R ₁ may comprise hydrophilic moieties such as polyether groups or ionically charged groups.

The individual radicals X may be branched or unbranched and may comprise substituted or unsubstituted alkylene groups and/or substituted or unsubstituted arylene groups.

The individual radicals X may comprise a heteroatom. It is preferred that X is bonded to its respective phosphorus atom via a carbon atom.

In the individual radicals ZH the placeholder “Z” is meant to denote a heteroatom such as nitrogen, oxygen or sulfur to which the NCO-reactive hydrogen atom is bonded. “Z” is not meant to comprise further atoms which are part of the connection to the terminal phosphorus atom. These atoms would be grouped into “X”.

In one embodiment at least one radical ZH is a hydroxyl group, a primary amino group or a secondary amino group. Preferred are the cases where all radicals ZH are hydroxyl groups or all radicals ZH are primary amino groups.

In another embodiment at least one radical X comprises one of the following groups: -B-CH ₂ -CH ₂ -, -Si-CH ₂ -CH ₂ - or -S-CH ₂ -CH ₂ -, wherein the -CH ₂ -CH ₂ - groups are located between the B, Si or S atoms and a P atom to which radicals R ₁ are bond. This structural feature can be created by addition of a molecule with a B-H, Si-H or S-H bond to a C=C double bond. In the case of an S-H bond this may be designated as a thiol-ene addition. The P atom to which radicals R1 are bond is a terminal P atom of the polyphosphazene chain. Ultimately, the C=C double bond precursor group is bond to the polyphosphazene chain before addition of the B/Si/S-H group containing compound.

In another embodiment least one radical X comprises one of the following groups:

(CH ₂ ) ₁₁₁ B , (CH2) _m Si or -(CH ₂ ) _m ^_ S- with m being an integer from 1 to 16, wherein the

(CH ₂ ) _m groups are located between the B, Si or S atoms and a radical ZH. This structural feature can be created starting from a compound with a HZ-(CH ₂ ) _m ^_ B/Si/S-H moiety which is then added to the polyphosphazene chain bearing a C=C double bond. Preferred values for m are ≥ 2 to ≤ 10. Particularly preferred are groups derived from mercaptoalkanols with 2, 3, 4, 5 or 6 carbon atoms or groups derived from mercaptoalkaneamines with 2, 3, 4, 5 or 6 carbon atoms.

In another embodiment at least one radical X-ZH comprises the group -Ar-CH ₂ -CH ₂ -S-(CH ₂ ) _m ^~ OH or -Ar-CH ₂ -CH ₂ -S-(CH ₂ ) _m -NH ₂ with m being an integer from 1 to 16 and Ar being a phenyl ring with or without additional substituents. This structural feature may be created by the reaction of a mercaptoalkanol or mercaptoalkaneamine with a styrene moiety bond to a terminal P atom of the polyphosphazene chain. Preferred values for m are ≥ 2 to ≤ 10. Particularly preferred are groups derived from mercaptoalkanols or mercaptoalkaneamines with 2, 3, 4, 5 or 6 carbon atoms.

In another embodiment at least one radical R comprises an oxygen or nitrogen atom bound to a phosphorus atom of a phosphazene group and/or at least one radical R ₁ is a substituted or unsubstituted phenyl group. Unsubstituted phenyl groups for R ₁ are preferred for reasons of commercial availability. With respect to R, a preferred radical group is -O-methyl/ethyl/propyl/butyl. Particularly preferred are ethoxy radicals for R. Another preferred group of radicals R derives from amino acid esters such as glycine esters, alanine esters, valine esters, isoleucine esters, leucine esters, methionine esters and phenylalanine esters. Examples for an alcohol moiety which is part of the amino acid esters include methyl, ethyl, propyl and butyl. If a radical R is said to derive from an amino acid ester, R would be the amino acid ester minus a hydrogen atom formerly bond to the amino group nitrogen atom of the amino acid. A third group of preferred radicals R are those derived from alkylaminomorpholines such as /V-(3-aminopropyl) morpholine.

The present invention also concerns a method of manufacturing a polyphosphazene according to the general formula (II). The method comprises reacting a C=C double bond-carrying compound of the general formula (III) with an element-hydrogen bond-carrying compound of the general formula H-E-L-ZH:

where: each radical E is, independent of other radicals E, B, Si or S; each radical L is, independent of other radicals L, an organic radical; each radical ZH is, independent of other radicals ZH, a group comprising an NCO-reactive hydrogen atom; each radical R is, independent of other radicals R, an organic radical which does not contain a terminal group with an NCO-reactive hydrogen atom; each radical R ₁ is, independent of other radicals R ₁ , an organic rest; each radical Y is, independent of other radicals Y, an organic rest and n is zero or a positive integer. The target molecule (II) may be seen as a case of a polyphosphazene of formula (I) where the radical X is the group Y-CH ₂ -CH ₂ -E-L. The reaction of H-E-L-ZH with (III) may be described, depending on the nature of E, a hydroboration, hydrosilylation or thiol-ene addition. Particularly preferred are mercaptoalkanols or mercaptoalkaneamines with 2, 3, 4, 5 or 6 carbon atoms as H-E-L-ZH. The degree of polymerization may be such that the number n in formulae (II) and (III) is ≥ 3 to ≤ 1000 and preferably ≥ 10 to ≤ 100. The definitions and preferred embodiments for R and R ₁ correspond to those outlined in conjunction with formula (I) above and shall not be repeated in the interest of brevity.

The radical Y is preferably a substituted or unsubstituted phenyl group. This has the advantage of the commercial availability of styrenic synthesis building blocks.

The reaction from (II) to (III) may take place under irradiation with UV light and/or in the presence of radical starters or catalysts if desired.

A polyurethane polymer can be obtained by reacting a polyphosphazene (I) according to the invention with a polyisocyanate. Preferably the polyphosphazene is of the structure (II). Examples for suitable polyisocyanates include methylene diphenyl diisocyanate (MDI), methylene dicyclohexyl diisocyanate (H12-MDI), polymeric MDI, toluylene diisocyanate (TDI), xylylene diisocyanate (XDI), pentamethylene diisocyanate (PDI), hexamethylene diisocyanate (HDI), isophorone diisocyanate (IPDI) and a mixture comprising at least two of the aforementioned polyisocyanates. Further suitable polyisocyanates include the prepolymers, isocyanurates, iminooxadiazinediones, allophanates, biurets and uretdiones of the afore-mentioned polyisocyanates. The polyurethane polymer may include polyol-derived building blocks different from polyphosphazenes (I) such as polyether polyol or polyester polyol building blocks, if desired. The polymer may be unfoamed or foamed material.

A method of manufacturing a polyurethane polymer comprises reacting a polyphosphazene (I) according to the invention with a polyisocyanate. Preferably the polyphosphazene is of the structure (II). Reference is made to the polyisocyanates mentioned above. The reaction mixture comprising the polyphosphazene (I) and the polyisocyanate may furthermore include polyester polyols and/or polyether polyols. With respect to catalysts, tin-free catalysts are preferred, especially if the polyurethane is to be used in medical applications. The NCO index (molar ratio of NCO groups to NCO-reactive H-atoms) in the reaction mixture may, for example, be in a range of 90 to 110. If desired, chemical and/or physical blowing agents may be added to the reaction mixture. Mechanical frothing of the reaction mixture is also possible.

In the event that the polyphosphazene comprises hydrophilic moieties, an aqueous preparation of the polyphosphazene may be reacted with the polyisocyanate. This allows for the in situ formation of a hydrogel. Alternatively or additionally, an aqueous preparation of the polyisocyanate may be used. However, careful reaction timing would then be required owing to the reactivity of polyisocyanates with water.

In an embodiment of the polyurethane polymer or the method of its manufacture the polyisocyanate is an NCO-terminated prepolymer obtained by the reaction of a monomeric polyisocyanate and a polyether polyol. Polyether polyols are advantageous as their hydrophilicity facilitates the formation of hydrogels. Preferred are poly (oxy ethylene) and poly(oxyethylene-co-propylene) polyols such as those obtained via double metal cyanide (DMC) catalysis. Particularly preferred are polyether polyols with ≥ 60 weight-% or ≥ 70 weight-% of ethylene oxide units, based on the total weight of the polyether polyol. Hydroxyl numbers (DIN 53240) of the polyol may be in the range of ≥ 20 mg KOH/g to ≤ 250 mg KOH/g, preferably ≥ 25 mg KOH/g to ≤ 50 mg KOH/g.

The polyol is preferably started on a short-chained polyalkylene oxide, for example on a glycerine -started poly(oxypropylene)triol with a hydroxyl number of ≥ 250 mg KOH/g to ≤ 400 mg KOH/g or a propylene glycol-started poly(oxypropylene)diol with a hydroxyl number of ≥ 200 mg KOH/g to ≤ 300 mg KOH/g.

With respect to the monomeric polyisocyanate, aliphatic diisocyanates such as pentamethylene diisocyanate, hexamethylene diisocyanate, isophorone diisocyanate, methylene dicyclohexyl diisocyanate and their isocyanurates, iminooxadiazinediones, allophanates, biurets and uretdiones are preferred. The NCO content of the prepolymer (DIN EN ISO 11909) may be in a range of ≥ 2% to ≤ 5%.

In another embodiment of the polyurethane polymer or the method of its manufacture the polyether polyol is a random copolymer of an alkylene oxide and a comonomer selected from: lactides, glycolides, cyclical dicarboxylic acid anhydrides and mixtures of at least two of the aforementioned compounds. These polyols have been found to be biodegradable owing to the incorporation of the comonomers. Details, including their synthesis, can be found in the published patent application WO 2013/092504 Al. It is preferred that the alkylene oxide is ethylene oxide and/or a mixture of ethylene oxide and propylene oxide. Hydroxyl numbers (DIN 53240) of the polyol may be in the range of ≥ 20 mg KOH/g to ≤ 250 mg KOH/g, preferably ≥ 25 mg KOH/g to ≤ 50 mg KOH/g.

The polyol is preferably started on a short-chained polyalkylene oxide, for example on a glycerine -started poly(oxypropylene)triol with a hydroxyl number of ≥ 250 mg KOH/g to ≤ 400 mg KOH/g or a propylene glycol-started poly(oxypropylene)diol with a hydroxyl number of ≥ 200 mg KOH/g to ≤ 300 mg KOH/g. The number average molecular weight of the polyol, as determined by gel permeation chromatography (THF as eluent, polystyrene standards), may be ≥ 200 g/mol to ≤ 10000 g/mol and preferably ≥ 1000 g/mol to ≤ 8000 g/mol.

The comonomer content may be ≥ 5 weight-% to ≤ 40 weight%, preferably ≥ 10 weight-% to ≤ 30 weight%, based on the total weight of the polyether polyol.. The comonomers may be used in their monomeric, dimeric, trimeric or polymeric forms, for example as dilactide in the case of lactides.

A hydrogel can be obtained by contacting a polyphosphazene (I) according to the invention and/or a polyurethane according to the invention with water. This is easily achievable by immersing the polyphosphazene or polyurethane in water. The water may be buffered, for example to a pH of 7.4.

In an embodiment the hydrogel further comprises, distributed within the hydrogel, a pharmaceutical compound, a pesticide, a herbicide, a pheromone or a combination of at least two of the aforementioned compounds. Suitable pharmaceutical compounds include:

1. Anti-inf ectives, such as antibiotics, including penicillin, tetracycline, chlortetracycline bacitracin, nystatin, streptomycin, neomycin, polymyxin, gramicidin, oxytetracycline, chloramphenicol, and erythromycin; sulfonamides, including sulfacetamide, sulfamethazine, sulfadiazine, sulfamerazine, sulfamethizole and sulfisoxazole; antivirals, including idoxuridine; and other anti-infectives including nitrofurazone and sodium propionate.

2. Anti-allergenics such as antazoline, methapyrilene, chlorpheniramine, pyrilamine and prophenpyridamine.

3. Anti-inflammatories such as hydrocortisone, cortisone, dexamethasone 21-phosphate, fluocinolone, triamcinolone, medrysone, prednisolone, prednisolone 21 -phosphate, and prednisolone acetate.

4. Decongestants such as phenylephrine, naphazoline, and tetrahydrazoline.

5. Miotics and antichlolinesterases such as pilocarpine, eserine salicylate, carbachol, di isopropyl fluorophosphate, phospholine iodide, demecarium bromide, physostigmin and neostigmin.

6. Mydriatics such as atropine sulfate, cyclopentolate, homatropine, scopolamine, tropicamide, eucatropine, and hydroxyamphetamine.

7. Sympathomimetics such as epinephrine.

8. Neuroleptics such as reserpine and chlorpromazine.

9. Estrogens such as estrone, 17//-cstradiol, ethinyl estradiol, and diethyl stilbesterol.

10. Progestational agents such as progesterone, 19-norprogesterone, norethindrone, megestrol, melengestrol, chlormadinone, ethisterone, medroxyprogesterone, norethynodrel and 17a- hydroxy-progesterone.

11. Humoral agents such as the prostaglandins, for example, PGE1, PGE2, and PGF2.

12. Antipyretics such as acetylsalicylic acid, sodium salicylate, and salicylamide.

13. Antispasmodics such as atropine, methantheline, papaverine, and methscopolamine bromide. 14. Cardioactive agents such as benzydroflumethiazide, flumethiazide, chlorothiazide, and aminotrate.

One type of preferred pharmaceutical compounds is a progestogen or a drug having a progestogenic activity. In particular the compound may be selected from the group of progesterone and its derivatives, cyproterone acetate, desogestrel, etonogestrel, levonorgestrel, lynestrenol, medroxyprogesterone acetate, norethisterone, norethisterone acetate, norgestimate, drospirenone, gestodene, 19-nor- 17-hydroxy progesterone esters, 17a- ethinyltestosterone and derivatives thereof, 17a-ethinyl-19-nor-testosterone and derivatives thereof, ethynodiol diacetate, dydrogesterone, norethynodrel, allylestrenol, medrogestone, norgestrienone, ethisterone, dl-norgestrel or a mixture of at least two of the aforementioned compounds.

Another type of preferred pharmaceutical compound is a drug capable of preventing or suppressing endometrial bleeding. In particular the compound may be selected from the group of prostaglandin synthesis inhibitors, NSAIDs, inhibitors of leukotriene, oxytocin antagonists, pancreatic trypsin inhibitors, COX-inhibitors, antifibrinolytic drugs, estrogens, antiestrogens, aromatase inhibitors, cytokine inhibitors, glucocorticoids, progestogens with pronounced glucocorticoid acticity, danazol, gestrinone, angiogenesis inhibitors or a mixture of at least two of the aforementioned compounds.

It is possible to combine the progestogen or a drug having a progestogenic activity with the drug capable of preventing or suppressing endometrial bleeding. Particularly preferred is the combination of levonorgestrel with tranexamic acid, mefenamic acid, danazol or an angiogenesis inhibitor. This is useful in an intrauterine device.

Another type of preferred pharmaceutical compound is a calcium channel blocker, in particular nimodipine or nifedipine.

Another type of preferred pharmaceutical compound is a cytostatic agent such as cisplatin, rituximab, bevacizumab, trastuzumab, imatinib, lenalidomide, pemetrexed, bortezomib, cetuximab, leuprolein or abiraterone.

Lastly, opioid analgetics and non-opioid analgetics are also a type of preferred pharmaceutical compound.

The pharmaceutical compounds (drugs) can be in different forms, such as uncharged molecules, components of molecular complexes, or non-irritating, pharmacologically acceptable salts such as hydrochloride, hydrobromide, sulphate, phosphate, nitrate, borate, acetate, maleate, tartrate, salicylate, etc. For acidic drugs, salts of metals, amines, or organic cations (e.g., quaternary ammonium) can be employed. Furthermore, simple derivatives of the drugs (such as ethers, esters, amides, etc.) which have desirable retention and release characteristics but which are easily hydrolyzed by body pH, enzymes, etc., can be employed.

Also contemplated are a hydrogel according to the invention for use as a post-operative separator between internal organs of a human or an animal and a hydrogel according to the invention for use as a delayed-release formulation for the pharmaceutical compound, pesticide, herbicide, pheromone or combination of at least two of the aforementioned compounds distributed within the hydrogel.

Post-operative separators (adhesion barriers) can be used to reduce or prevent unwanted tissue adhesions in a patient after surgery by separating the internal tissues and organs while they heal. The prevention of intraabdominal adhesions is expressly contemplated.

In its use as a delayed release formulation the hydrogel can be viewed as a drug delivery device or system. Drug delivery systems of the invention can take a wide variety of shapes and forms for administering the drugs at controlled rates to different areas of the body. Thus, the invention includes external and internal drug-delivery systems such as skin patches, sublingual or buccal tablets, peroral dosage forms, implantates for releasing a drug in the tissues of a living organism, pessaries, prosthesis, artificial glands, vaginal or rectal suppositories, cervical rings, troches, drug-dispensing intrauterine devices and ocular inserts.

Examples

The present invention will be further described in the following examples and figures without wishing to be limited to them.

Synthesis of a, w-distyryl poly[(dichloro)phosphazenes] (3) - Figure 1

The synthesis of the chlorinated, styrene-functionalized k ⁵ -phosphane mediator was carried out according to literature (Wilfert, S.; Henke, H.; Schoefberger, W.; Briiggemann, O.; Teasdale, I., Chain-End-Functionalized Polyphosphazenes via a One-Pot Phosphine-Mediated Living Polymerization. Macromol. Rapid Commun. 2014, 35 (12), 1135-1141).

4-(Diphenylphosphino)styrene (0.58 g, 2.01 mmol, 1 equiv.) and hexachloroethane (0.52 g, 2.21 mmol, 1.1 equiv.) were dissolved in 2 mL of anhydrous dichloromethane and stirred at room temperature for 24 h to yield di chlorodi phenyl (4-vi nyl phenyl )-/2-ph sphanc. which was used for subsequent reactions without further purification. Yield: quantitative; ³¹ P{¾} NMR (121 MHz, CDC1 ₃ , δ): 63.33 (R ₃ P=N-) ppm.

Dichlorodiphenyl(4-vinylphenyl)-k ⁵ -phosphane (2.01 mmol, 1 equiv.) was reacted with /V-(ti'imcthylsilyl)-ti'ichloi'ophosphoraniminc (3.16 g, 14.08 mmol, 7 equiv.) in 5 mL of anhydrous dichloromethane and stirred at room temperature for 12 h to yield a- poly[(dichloro)phosphazene] 1, which was used for subsequent reactions without further purification. Yield: quantitative; ³¹ P ( ¹ H } NMR (121 MHz, CDC1 ₃ , δ): -18.19 (-Cl ₂ P=N-), 8.09 (-PCI ₃ ), 19.50 (Ph ₃ P=N-) ppm.

4-(Diphenylphosphino)styrene (0.87 g, 3.08 mmol, 1 equiv.) and trimethylsilyl azide (1.39 g, 12.07 mmol, 4 equiv.) were dissolved in 25 mL of anhydrous dichloromethane. According to the ³¹ P NMR spectrum, the reaction was completed after stirring for 96 h at room temperature. Next, vacuum distillation was used to remove the excess of the azide in the solution after the reaction. This was achieved by transferring the solution into a Schlenk Tube and evaporating the solvent under reduced pressure obtaining the yellow, waxy-solid 1 , 1 -di phenyl -/V-(trimcthylsilyl)- 1 -(4-vinylphcnyl)-/7-phosphaniminc (/V-organophosphoranimine) 2. Yield: 0.76 g (87 %); 'H NMR (300 MHz, CDC1 ₃ , d): -0.18 (s, 1.5H, -CH ₃ ), -0.05 (s, 6H, -CH ₃ ), 0.08 (s, 0.5H, -CH ₃ ), 0.17 (s, 1H, -CH ₃ ), 5.34 (dd, 1H, -CH =CH ₂ ), 5.83 (dd, 1H, -CH =CH ₂ ), 6.74 (dd, 1H, -CH= CH ₂ ), 7.58 (m, 14H, -Ph ₃ ) ppm; ³¹ P{ ¹ H} NMR (121 MHz, CDC1 ₃ , d): 0.49 (R ₃ P=N-) ppm.

The /V-organophosphoranimine 2 (1.13 g, 3.02 mmol, 1.5 equiv.) was dissolved in 8 mL of anhydrous dichloromethane, added to the solution of α-poly[(dichloro)phosphazene] 3 (2.01 mmol, 1 equiv.) in anhydrous dichloromethane and stirred at room temperature for 24 h until completion of the reaction, based on the ³¹ P NMR spectrum. The obtained solution of the end-capped α-w-distyryl poly[(dichloro)phosphazene] 3 was used for subsequent reactions without further purification. Yield: quantitative; ³¹ P{ ¹ H} NMR (121 MHz, CDC1 ₃ , d): -18.21 (-C1 ₂ P=N-), 18.01 (-N=PPh ₃ ), 19.48 (Ph ₃ P=N-) ppm.

Synthesis of a, w-distyryl polyorganophosphazenes 4, 5 and 6 - Figure 2

Starting from 3, α, ω -distyryl polyorganophosphazenes were synthesized as follows:

The synthesis of α-ω-distyryl poly[bis(ethoxy)phosphazene] 4 was carried as follows: Sodium ethoxide was generated in situ by gradually dissolving sodium metal (1.17 g, 50.81 mmol, 1 equiv.) in anhydrous ethanol (29.67 mL, 0.54 mol, 10 equiv.) and stirring the solution for 48 h under a nitrogen stream, which was used to evaporate unreacted amounts of ethanol after the sodium metal was completely dissolved in the solution. The obtained solid white, dry sodium ethoxide (3.46 g, 50.81 mmol, 24.5 equiv.) was dissolved in 50 mL of anhydrous tetrahydrofuran and a solution of α-w-distyryl poly[(dichloro)phosphazene] (1 equiv.) in 10 mL of anhydrous dichloromethane was added dropwise. According to the ³¹ P NMR spectrum, the reaction was completed after stirring for 96 h at room temperature. The solution was then centrifuged, the precipitate removed and the solvent was removed under reduced pressure to yield a solid-waxy brown-yellow product. Next, the polymer was dissolved in 10 mL of anhydrous ethanol and purified by dialysis against ethanol for 48 h (1 kDa cut-off). Finally, the solvent was removed under reduced pressure and the pale-yellowish product was dried further under vacuum at 45 °C for 24 h.

Yield: 1.40 g (41 %); ¹ H NMR (300 MHz, CDCI ₃ , δ): 1.29 (br, 26H, -CH ₂ -CH ₃ ), 4.15 (br, 18H, -CH ₂ - CH ₃ ), 5.42 (br, 2H, -CH =CH ₂ ), 5.88 (br, 2H, -CH =CH ₂ ), 6.75 (br, 2H, -CH= CH ₂ ), 7.61 (br, 28H, -Ph ₃ ) ppm; ³¹ P{ ¹ H} NMR (121 MHz, CDC1 ₃ , δ): -1.39 (-C1 ₂ P=N-), 13.76 (- N=PPh ₃ ), 15.08 (Ph ₃ P=N-) ppm.

The synthesis of α-ω-distyryl poly[bis(glycine ethyl ester)phosphazene] 5 was synthesized as follows: Glycine ethyl ester hydrochloride (13.76 g, 98.57 mmol, 1 equiv.) was dissolved in 100 mL of anhydrous tetrahydrofuran, and triethylamine (27.25 mL, 0.197 mol, 2 equiv.) was added. The solution was stirred at room temperature for 48 h, filtered and the solvent removed under reduced pressure. The obtained glycine ethyl ester (5.24 g, 50.87 mmol, 24.5 equiv.) was dissolved in 40 mL of anhydrous tetrahydrofuran and triethylamine (14.05 mL, 0.102 mol, 49 equiv.) was added. Next, a solution of α-ω-distyryl poly[(dichloro)phosphazene] (1 equiv.) in 10 mL of anhydrous dichloromethane was added dropwise. According to the ³¹ P NMR spectrum, the reaction was completed after stirring for 24 h at room temperature. The solution was then filtered and the solvent removed under reduced pressure to yield a waxy, yellow product. Next, the polymer was dissolved in 10 mL of anhydrous ethanol and purified by dialysis against ethanol for 48 h (1 kDa cut-off). Finally, the solvent was removed under reduced pressure and the orange-yellowish product was dried further under vacuum at 45 °C for 24 h.

Yield: 2.68 g (50 %); ¹ H NMR (300 MHz, CDC1 ₃ , δ): 1.22 (br, 60H, -CH ₂ -CH ₃ ), 3.70 (br, 40H, -NH-CH ₂ -), 4.11 (br, 45H, -CH ₂ - CH ₃ ), 5.41 (br, 2H, -CH =CH ₂ ), 5.88 (br, 2H, -CH =CH ₂ ), 6.74 (br, 2H, -CH= CH ₂ ), 7.60 (br, 28H, -Ph ₃ ) ppm; ³¹ P{ ¹ H} NMR (121 MHz, CDCL, d): 1.02 (-C1 ₂ P=N-), 10.78 (-N=PPh ₃ ), 12.04 (Ph ₃ P=N-) ppm.

The α-ω-distyryl poly[bis(/V-(3-aminopropyl)morpholine)phosphazene] 6 was prepared by dissolving /V-(3-aminopropyl)morpholine (6.36 mL, 43.55 mmol, 24.5 equiv.) in 40 mL of anhydrous tetrahydrofuran and adding triethylamine (12.04 mL, 87.10 mol, 49 equiv.). Next, a solution of α-ω-distyryl poly[(dichloro)phosphazene] (1 equiv.) in 10 mL of anhydrous dichloromethane was added dropwise. According to the ³¹ P NMR spectrum, the reaction was completed after stirring for 24 h at room temperature. The solution was then filtered and the solvent removed under reduced pressure to yield a waxy, orange-yellow product. Next, the polymer was dissolved in 10 mL of anhydrous ethanol and purified by dialysis against ethanol for 48 h (1 kDa cut-off). Finally, the solvent was removed under reduced pressure and the orange product was dried further under vacuum at 45 °C for 24 h.

Yield: 4.55 g (67 %); ¹ H NMR (300 MHz, CDC1 ₃ , δ): 1.67 (br, 26H, -CH ₂ -CH ₂ -CH ₂ -), 2.41 (br, 80H, -CH ₂ -CH ₂ NH-CH ₂ -), 2.88 (br, 26H, -NH-CH ₂ -), 3.68 (br, 55H, -CH ₂ -O-CH ₂ -), 5.43 (br, 2H, -CH =CH ₂ ), 5.88 (br, 2H, -CH =CH ₂ ), 6.74 (br, 2H, -CH= CH ₂ ), 7.59 (br, 28H, -Ph ₃ ) ppm; ³¹ P{ ¹ H} NMR (121 MHz, CDC1 ₃ , δ): -3.57 (-C1 ₂ P=N-), 11.25 (Ph ₃ P=N-) ppm.

Functionalization the a-w-terminal double bonds of polymer 6 - Figure 3

The following procedure describes an example of functionalization the α-ω-terminal double bonds of polymer 6 using the thiol-ene photoreaction with 6-mercapto-l-hexanol. α-ω-distyryl poly[bis(/V-(3-aminopropyl)morpholine)phosphazene] (300 mg, 0.0885 mmol, 1 equiv.) and 2,2-dimethoxy-2-phenylacetophenone (30 g, 10 w%) were dissolved in 5 mL of anhydrous ethanol in a non-UV-absorbing flask. Next, 6-mercapto-l-hexanol (23.77 mg, 0.117 mmol, 2 equiv.) was added. The flask was then sealed with a rubber septum and flushed with argon for 10 minutes. The solution was then stirred and irradiated with UV light at 4 °C overnight. Completion of the reaction was controlled by 'H NMR spectroscopy. After the reaction was finished, the solvent was removed under reduced pressure. 20 mL of dichloromethane were added to re-dissolve the obtained α-ω-diol poly[bis(/V-(3-aminopropyl)morpholine)phosphazene] and the solvent was removed again under reduced pressure to remove ethanol residues in the polymer. Finally, the polymer was dissolved in anhydrous tetrahydrofuran and used for subsequent reactions without further purification. Yield: quantitative.

Polyurethane synthesis with polyphosphazene diols - Figure 4

Poly(hexamethylene diisocyanate) (HDI biuret and oligomers; 1 NCO-equiv.) was added to a solution of α-ω-diol poly[bis(/V-(3-aminopropyl)morpholine)phosphazene] (1 equiv.) in anhydrous tetrahydrofuran and stirred for 4 h at 50 °C. After the reaction, the solvent was removed under reduced pressure and the solid, orange-yellowish polyurethane was dried further under vacuum at 45 °C for 24 h. Yield: quantitative; FT-IR (v): 3273 ( -NH- ), 3057 (- Ar-H), 2932-2807 (-CH ₂ -), 1764 (-C=0-), 1688 (-NH-CO-), 1525 (-NH-CO-), 1233 (- P=N -), 860 (-P-N-) cm ¹ .